Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD

Bayer, Antony James, Bullock, R., Jones, R. W., Paterson, K. R., Jenkins, L., Millais, S. B. and Donoghue, S. 2005. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 64 (1) , pp. 94-101. 10.1212/01.WNL.0000148604.77591.67

Full text not available from this repository.

Abstract

Background: Aβ42-immunization reduces plaque burden and improves cognition in transgenic mouse models of Alzheimer disease (AD). This phase 1 study evaluated the safety, tolerability, and immunogenicity of AN1792 (human aggregated Aβ42) in patients with mild to moderate AD. Methods: Twenty patients were enrolled into each of four dose groups and randomly assigned to receive IM AN1792 (50 or 225 μg) with QS-21 adjuvant (50 or 100 μg) or QS-21 only (control) in a 4:1 active:control ratio on day 0 and at weeks 4, 12, and 24. Patients could receive up to four additional injections of a polysorbate 80 modified formulation at weeks 36, 48, 60, and 72. Safety, tolerability, immunogenicity, and exploratory evidence of efficacy were evaluated. Results: Treatment-related adverse events were reported in 19 (23.8%) patients, but no relationship was observed between AN1792 dose and incidence. One patient developed meningoencephalitis that was diagnosed after death (not directly related to study treatment) and 219 days after discontinuing from the study. Five deaths occurred during the study follow-up, but none was considered to be directly related to study treatment. During the period of the first four injections, 23.4% of AN1792-treated patients had a positive anti-AN1792 antibody titer (an anti-AN1792 antibody titer of ≥1:1,000). This increased to 58.8% after additional injections with the modified formulation. Disability Assessment for Dementia scores showed less decline among active compared with control patients at week 84 (p = 0.002). No treatment differences were observed in three other efficacy measures. Conclusions: AN1792 + QS-21 elicited a positive antibody response to Aβ42 in more than half of this elderly study population.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: Q Science > QH Natural history > QH426 Genetics
Q Science > QR Microbiology > QR180 Immunology
R Medicine > R Medicine (General)
Publisher: Lippincott, Williams & Wilkins
ISSN: 0028-3878
Last Modified: 04 Jun 2017 05:03
URI: http://orca.cf.ac.uk/id/eprint/47889

Citation Data

Cited 277 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item